TABLE OF CONTENTS
1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 11
1.3 OVERVIEW OF THE U.S. SECONDARY HYPEROXALURIA DRUG MARKET 11
1.4 LIMITATIONS 13
1.5 MARKETS COVERED 13
2 MARKET SEGMENTATION 15
2.1 MARKETS COVERED 15
2.2 GEOGRAPHICAL SCOPE 16
2.3 YEARS CONSIDERED FOR THE STUDY 16
2.4 CURRENCY AND PRICING 16
2.5 DBMR TRIPOD DATA VALIDATION MODEL 17
2.6 MULTIVARIATE MODELLING 20
2.7 TYPE LIFELINE CURVE 20
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 21
2.9 DBMR MARKET POSITION GRID 22
2.10 MARKET END USER COVERAGE GRID 23
2.11 VENDOR SHARE ANALYSIS 24
2.12 SECONDARY SOURCES 25
2.13 ASSUMPTIONS 25
3 EXECUTIVE SUMMARY 26
4 PIPELINE ANALYSIS 29
5 REGULATORY SCENARIO OF THE U.S. SECONDARY HYPEROXALURIA DRUG MARKET 30
6 EPIDEMIOLOGY 32
7 MARKET OVERVIEW 33
7.1 DRIVERS 35
7.1.1 HIGH DEMAND OF DISEASE SPECIFIC NOVEL TREATMENT 35
7.1.2 INCREASED INVESTMENT IN R&D 35
7.1.3 LOW DIETARY AWARENESS IN SOCIETY 36
7.1.4 INCREASED NUMBER OF CASES FOR SECONDARY HYPEROXALURIA 36
7.1.5 LOSS OF OXALOBACTER FORMIGENES 36
_
7.2 RESTRAINTS 37
7.2.1 LIMITED OPERATING REVENUE 37
7.2.2 HIGH COST OF TREATING SECONDARY HYPEROXALURIA 37
7.2.3 LIMITED SECONDARY THERAPEUTICS OPTION FOR TREATMENT 38
7.3 OPPORTUNITIES 38
7.3.1 DIFFICULTY IN MAINTAINING LOW OXALATE DIET 38
7.3.2 STRONG REIMBURSEMENT POLICIES IN THE U.S. 39
7.3.3 REGULATORY SUPPORT FOR APPROVAL 39
7.3.4 RISING DISPOSABLE INCOME 40
7.4 CHALLENGES 40
7.4.1 DELAY IN DIAGNOSIS OF DISEASE LEADING TO NEED FOR RENAL REPLACEMENT 40
7.4.2 INCREASE FITNESS AWARENESS AMONG PEOPLE 40
7.4.3 INCREASE FLUID INTAKE AS A PREVENTIVE MEASURES 41
8 COVID-19 IMPACT ON THE U.S. SECONDARY HYPEROXALURIA DRUG MARKET 42
8.1 OVERVIEW 43
8.2 PRICE IMPACT 43
8.3 IMPACT ON DEMAND 43
8.4 IMPACT ON SUPPLY CHAIN 44
8.5 STRATEGIC DECISIONS FOR MANUFACTURERS 44
8.6 CONCLUSION 44
9 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE 46
9.1 OVERVIEW 47
9.2 SUPPLEMENTS 50
9.2.1 OXALATE BINDING AGENTS 51
9.2.1.1 CALCIUM SUPPLEMENTS 51
9.2.1.2 MAGNESIUM SUPPLEMENTS 51
9.2.1.3 OTHERS 51
9.2.2 CITRATE SUPPLEMENTS 51
9.2.3 PYRIDOXINE SUPPLEMENTS 51
9.2.4 PROBIOTICS 51
9.3 THIAZIDE DIURETICS 51
9.4 RELOXALIASE 52
10 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE 53
10.1 OVERVIEW 54
10.2 OVER THE COUNTER 57
10.3 PRESCRIPTION 57
_
11 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE 58
11.1 OVERVIEW 59
11.2 ADULTS 62
11.3 CHILDREN 62
12 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER 63
12.1 OVERVIEW 64
12.2 HOME HEALTHCARE 67
12.3 HOSPITALS 67
12.4 SPECIALTY CLINICS 67
12.5 OTHERS 68
13 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL 69
13.1 OVERVIEW 70
13.2 RETAIL PHARMACY 73
13.3 HOSPITAL PHARMACY 73
13.4 ONLINE PHARMACY 73
13.5 OTHERS 74
14 U.S. SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY LANDSCAPE 75
14.1 COMPANY SHARE ANALYSIS: U.S. 75
15 SWOT 76
16 COMPANY PROFILES 77
16.1 NESTLE 77
16.1.1 COMPANY SNAPSHOT 77
16.1.2 REVENUE ANALYSIS 77
16.1.3 PRODUCT PORTFOLIO 78
16.1.4 RECENT DEVELOPMENTS 78
16.2 GLAXOSMITHKLINE PLC 79
16.2.1 COMPANY SNAPSHOT 79
16.2.2 REVENUE ANALYSIS 79
16.2.3 PRODUCT PORTFOLIO 80
16.2.4 RECENT DEVELOPMENT 80
16.3 BAYER AG 81
16.3.1 COMPANY SNAPSHOT 81
16.3.2 REVENUE ANALYSIS 81
16.3.3 PRODUCT PORTFOLIO 82
16.3.4 RECENT DEVELOPMENTS 82
_
16.4 PHARMAVITE 83
16.4.1 COMPANY SNAPSHOT 83
16.4.2 PRODUCT PORTFOLIO 83
16.4.3 RECENT DEVELOPMENTS 83
16.5 SOLGAR INC. 85
16.5.1 COMPANY SNAPSHOT 85
16.5.2 PRODUCT PORTFOLIO 85
16.5.3 RECENT DEVELOPMENT 86
16.6 MISSION PHARMACAL COMPANY 87
16.6.1 COMPANY SNAPSHOT 87
16.6.2 PRODUCT PORTFOLIO 87
16.6.3 RECENT DEVELOPMENT 87
16.7 OYSTER SHELL 88
16.7.1 COMPANY SNAPSHOT 88
16.7.2 PRODUCT PORTFOLIO 88
16.7.3 RECENT DEVELOPMENT 88
16.8 ALLENA PHARMACEUTICALS, INC. 89
16.8.1 COMPANY SNAPSHOT 89
16.8.2 PRODUCT PORTFOLIO 89
16.8.3 RECENT DEVELOPMENTS 89
16.9 CELEBRATE VITAMINS 91
16.9.1 COMPANY SNAPSHOT 91
16.9.2 PRODUCT PORTFOLIO 91
16.9.3 RECENT DEVELOPMENT 91
16.10 ENTRING, LLC 92
16.10.1 COMPANY SNAPSHOT 92
16.10.2 PRODUCT PORTFOLIO 92
16.10.3 RECENT DEVELOPMENTS 92
16.11 OXTHERA 93
16.11.1 COMPANY SNAPSHOT 93
16.11.2 PRODUCT PORTFOLIO 93
16.11.3 RECENT DEVELOPMENT 93
16.12 RENEW LIFE FORMULAS, INC. 94
16.12.1 COMPANY SNAPSHOT 94
16.12.2 PRODUCT PORTFOLIO 94
16.12.3 RECENT DEVELOPMENTS 95
_
16.13 SYNLOGIC 96
16.13.1 COMPANY SNAPSHOT 96
16.13.2 REVENUE ANALYSIS 96
16.13.3 PRODUCT PORTFOLIO 97
16.13.4 RECENT DEVELOPMENTS 97
17 QUESTIONNAIRE 98
18 RELATED REPORTS 101

 

Research Methodology

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analysing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.